Literature DB >> 12759294

Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis.

P Alba1, L Bento, M J Cuadrado, Y Karim, M F Tungekar, I Abbs, M A Khamashta, D D'Cruz, G R V Hughes.   

Abstract

BACKGROUND: Lupus nephritis (LN) is a common manifestation in patients with systemic lupus erythematosus (SLE). Autoantibodies and ethnicity have been associated with LN, but the results are controversial.
OBJECTIVE: To study the immunological and demographic factors associated with the development of LN. PATIENTS AND METHODS: A retrospective case-control study of 127 patients with biopsy-proven LN, and 206 randomly selected patients with SLE without nephritis as controls was designed. All patients had attended our lupus unit during the past 12 years. Standard methods were used for laboratory testing.
RESULTS: Patients with LN were significantly younger than the controls at the time of SLE diagnosis (mean (SD) 25.6 (8.8) years v 33.7 (12.5) years; p<0.0001). The proportion of patients of black ethnic origin was significantly higher in the group with nephritis (p=0.02). There were no differences in sex distribution or duration of follow up. A higher proportion of anti-dsDNA, anti-RNP, anti-Sm, and lupus anticoagulant (LA) was seen in the group with nephritis (p=0.002; p=0.005; p=0.0001; p=0.01, respectively). In univariate, but not in multivariate, analysis male sex and absence of anti-dsDNA were associated with earlier onset of renal disease (p=0.03; p=0.008). In multivariate analysis the only factors associated with nephritis were younger age at diagnosis of SLE, black race, presence of anti-dsDNA, anti-Sm, and LA. No demographic or immunological associations were seen with WHO histological classes.
CONCLUSIONS: Young, black patients with anti-dsDNA, anti-Sm antibodies, and positive LA, appear to have a higher risk of renal involvement. These patients should be carefully monitored for the development of LN.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759294      PMCID: PMC1754557          DOI: 10.1136/ard.62.6.556

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  35 in total

1.  Long-term follow-up of autoantibody profiles in black female lupus patients and clinical comparison with Caucasian and Asian patients.

Authors:  D A Isenberg; M Garton; M W Reichlin; M Reichlin
Journal:  Br J Rheumatol       Date:  1997-02

Review 2.  Clinical connections: assays and assignment.

Authors:  D A Bell; R J Smeenk
Journal:  Lupus       Date:  1997       Impact factor: 2.911

3.  Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH.

Authors:  J T Brandt; D A Triplett; B Alving; I Scharrer
Journal:  Thromb Haemost       Date:  1995-10       Impact factor: 5.249

4.  Glomerular binding activity in MRL lpr serum consists of antibodies that bind to a DNA/histone/type IV collagen complex.

Authors:  K A Bernstein; R D Valerio; J B Lefkowith
Journal:  J Immunol       Date:  1995-03-01       Impact factor: 5.422

5.  Absence of a distinctive autoantibody profile in black women with lupus nephritis: comment on the article by McCarty et al.

Authors:  J Joseph; J M Anaya; M Sandifer; E Scopelitis; W Wilson; L R Espinoza
Journal:  Arthritis Rheum       Date:  1994-08

6.  [Clinical expression of systemic lupus erythematosus with anti-U1-RNP and anti-Sm antibodies].

Authors:  F J López-Longo; C M González Fernández; M Rodríguez Mahou; R Grau Simó; I Monteagudo Sáez; A C Meno García; L Carreño Pérez
Journal:  Rev Clin Esp       Date:  1997-05       Impact factor: 1.556

7.  Autoantibody profile in African-American patients with lupus nephritis.

Authors:  C O García; J F Molina; S Gutiérrez-Ureña; E Scopelitis; W A Wilson; A E Gharavi; L R Espinoza
Journal:  Lupus       Date:  1996-12       Impact factor: 2.911

8.  Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus.

Authors:  R Cervera; M A Khamashta; J Font; G D Sebastiani; A Gil; P Lavilla; I Doménech; A O Aydintug; A Jedryka-Góral; E de Ramón
Journal:  Medicine (Baltimore)       Date:  1993-03       Impact factor: 1.889

9.  A distinctive autoantibody profile in black female patients with lupus nephritis.

Authors:  G A McCarty; J B Harley; M Reichlin
Journal:  Arthritis Rheum       Date:  1993-11

10.  Mutational analysis of an autoantibody: differential binding and pathogenicity.

Authors:  J B Katz; W Limpanasithikul; B Diamond
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  68 in total

Review 1.  Lupus nephritis in Colombians: contrasts and comparisons with other populations.

Authors:  Juan-Manuel Anaya; Carlos Cañas; Rubén D Mantilla; Ricardo Pineda-Tamayo; Gabriel J Tobón; Catalina Herrera-Diaz; Diego M Rendón; Adriana Rojas-Villarraga; Mauricio Uribe
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

2.  Administration of activated lymphocyte-derived DNA accelerates and aggravates lupus nephritis in B6/lpr mice: a new approach to modify a lupus murine model.

Authors:  Y Zhu; Y Yue; S Xiong
Journal:  Clin Exp Immunol       Date:  2018-07-23       Impact factor: 4.330

3.  Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus.

Authors:  Sung Soo Ahn; Seung Min Jung; Juyoung Yoo; Sang-Won Lee; Jason Jungsik Song; Yong-Beom Park
Journal:  Rheumatol Int       Date:  2019-09-24       Impact factor: 2.631

4.  CD74 Deficiency Mitigates Systemic Lupus Erythematosus-like Autoimmunity and Pathological Findings in Mice.

Authors:  Yi Zhou; Huimei Chen; Li Liu; Xueqing Yu; Galina K Sukhova; Min Yang; Lijun Zhang; Vasileios C Kyttaris; George C Tsokos; Isaac E Stillman; Takaharu Ichimura; Joseph V Bonventre; Peter Libby; Guo-Ping Shi
Journal:  J Immunol       Date:  2017-02-20       Impact factor: 5.422

Review 5.  The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease.

Authors:  Alina Dima; Ciprian Jurcut; Cristian Baicus
Journal:  Rheumatol Int       Date:  2018-05-23       Impact factor: 2.631

Review 6.  The mechanisms and applications of T cell vaccination for autoimmune diseases: a comprehensive review.

Authors:  Xin Huang; Haijing Wu; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

Review 7.  Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future.

Authors:  Noam Jacob; William Stohl
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

Review 8.  B-cell-targeted therapies in systemic lupus erythematosus.

Authors:  Vera Sau-Fong Chan; Helen Hoi-Lun Tsang; Rachel Chun-Yee Tam; Liwei Lu; Chak-Sing Lau
Journal:  Cell Mol Immunol       Date:  2013-01-28       Impact factor: 11.530

9.  TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression.

Authors:  Tanvi Arkatkar; Holly M Jacobs; Samuel W Du; Quan-Zhen Li; Kelly L Hudkins; Charles E Alpers; David J Rawlings; Shaun W Jackson
Journal:  Kidney Int       Date:  2018-06-12       Impact factor: 10.612

Review 10.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.